These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2519630)

  • 1. Kinetics of destruction and regeneration of the haemopoietic system after administration of busulphan and cyclophosphamide followed by bone marrow transplantation. Peripheral blood parameters.
    Szczylik C; Ratajczak MZ; Urbanowska E; Jedrzejczak WW
    Acta Med Pol; 1989; 30(3-4):93-109. PubMed ID: 2519630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children.
    Shaw PJ; Hugh-Jones K; Hobbs JR; Downie CJ; Barnes R
    Bone Marrow Transplant; 1986 Dec; 1(2):193-200. PubMed ID: 3332132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of hematopoietic engraftment after bone marrow and peripheral blood stem cell transplantation by highly fluorescent reticulocyte counts.
    Greinix HT; Linkesch W; Keil F; Kalhs P; Schwarzinger I; Schneider B; Oesterreicher C; Brugger S; Kapiotis S; Lechner K
    Bone Marrow Transplant; 1994 Aug; 14(2):307-13. PubMed ID: 7994247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide.
    Yamaguchi M; Nakao S; Ueda M; Takamatsu H; Tamaru Y; Shiobara S; Masauji N; Matsue K; Matsuda T
    Bone Marrow Transplant; 1995 May; 15(5):787-9. PubMed ID: 7670408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Platelet function after allogeneic bone marrow transplantation in Wiskott-Aldrich syndrome].
    Megido M; Cesar JM; Maldonado MS; Otheo E; Muñoz A; Navarro JL
    Sangre (Barc); 1993 Jun; 38(3):233-4. PubMed ID: 8211550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children.
    Hobbs JR; Hugh-Jones K; Shaw PJ; Downie CJ; Williamson S
    Bone Marrow Transplant; 1986 Dec; 1(2):201-8. PubMed ID: 2971409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
    Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P
    Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow transplantation from unrelated donors for genetic diseases following conditioning with Busulphan and Cyclophosphamide.
    Vellodi A; Jurges E; el-Tumi M; Abdul-Ahad A; Hobbs JR
    Bone Marrow Transplant; 1991; 7 Suppl 2():70. PubMed ID: 1878726
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
    Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
    Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of hematopoietic progenitor cells in thalassemia after bone marrow transplantation.
    Tang-naitrisorana Y; Issaragrisil S; Visuthisakchai S; Suvatte V; Piankijakum A
    Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():291-5. PubMed ID: 8629127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of erythropoietic/hematopoietic reconstitution after BMT by highly fluorescent reticulocyte counts compares favorably with traditional peripheral blood cell counting.
    Kanold J; Bezou MJ; Coulet M; Quainon F; Malpuech G; Travade P; Deméocq F
    Bone Marrow Transplant; 1993 Apr; 11(4):313-8. PubMed ID: 7683553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in levels of electrolytes in serum of patients with allogenic bone marrow transplants].
    Ratajczak MZ; Jedrzejczak WW
    Pol Tyg Lek; 1991 Oct 28-Nov 4; 46(43-44):829-33. PubMed ID: 1669172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal irradiation on hematopoietic recovery.
    Faulkner LB; Lindsley KL; Kher U; Heller G; Black P; Finlay JL
    Bone Marrow Transplant; 1996 Mar; 17(3):389-94. PubMed ID: 8704692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
    Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urothelial cell changes due to busulfan and cyclophosphamide treatment in bone marrow transplantation.
    Stella F; Battistelli S; Marcheggiani F; De Santis M; Giardini C; Baronciani D; Manenti F; Mattioli S; Troccoli R
    Acta Cytol; 1990; 34(6):885-90. PubMed ID: 2256423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.
    Thomas AE; Patterson J; Prentice HG; Brenner MK; Ganczakowski M; Hancock JF; Pattinson JK; Blacklock HA; Hopewell JP
    Bone Marrow Transplant; 1987 Apr; 1(4):347-55. PubMed ID: 3139113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
    Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
    Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.